Background: There is no standard management of chronic hepatitis B (CHB) patients with suboptimal response to nucleoside/nucleotide analogues (NAs). This study aimed to evaluate two different NA combination therapies in patients with suboptimal response to adefovir (ADV).
Methods: In this study, 72 CHB patients with suboptimal response to ADV were assessed, with 37 patients receiving lamivudine plus ADV (group A) and 35 patients receiving telbivudine plus ADV (group B).
Results: Baseline characteristics between two groups were similar. At month 12, rates of biochemical response (BR) and virological response (VR) were similar between groups A and B (17/19 versus 18/20 for BR, [P=0.269] and 30/37 versus 31/35 for VR [P=0.377]), and cumulative rates of serological response were greater in group B than in group A (10/26 versus 2/28 in hepatitis B e antigen [HBeAg] loss [P=0.006] and 7/26 versus 1/28 in HBeAg/hepatitis B e antibody seroconversion [P=0.022]). After 12-month treatment, 8.1% (3/37) of patients in group A and 5.7% (2/35) of patients in group B had VR; among patients in group A, two had rtM204V/I and rtL180M and one had rtN236T, whereas the two patients in group B had rtM204I+rtL180M.
Conclusions: Both combination therapies led to a significant decrease in HBV DNA. HBeAg serological outcomes were higher with telbivudine plus ADV combination therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3851/IMP2190 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Macedo ileum-based reservoir for the management of bladder involvement in epidermolysis bullosa.
J Pediatr Urol
December 2024
Department of Pediatric Surgery and Urology, Medical University of Silesia, ul. Medyków 16, 40-752, Katowice, Poland.
Introduction: Epidermolysis bullosa (EB) can severely affect the urinary tract, leading to strictures and urine outflow obstruction, which pose significant risks to kidney function. Procedures involving the urinary mucosa often exacerbate these issues, making safe bladder emptying a major challenge. This study reviews surgical methods for managing urological complications in EB patients, with a focus on the Macedo procedure, which offers a promising alternative that avoids further bladder mucosa irritation and prevents disease exacerbation.
View Article and Find Full Text PDFConcomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211.
Urol Oncol
January 2025
Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, TX; Department of Urology, University of Cincinnati, Cincinnati, Ohio. Electronic address:
Objectives: Survival outcomes of patients with metastatic urothelial carcinoma (mUC) are still suboptimal and strategies to enhance response to immune-oncology (IO) compounds are under scrutiny. In preclinical studies, it has been demonstrated that antihistamines may reverse macrophage immunosuppression, reactivate T cell cytotoxicity, and enhance the immunotherapy response. We aimed to evaluate the role of concomitant antihistamines administration on oncological outcomes among patients with mUC.
View Article and Find Full Text PDFEffects of a 4week internetdelivered mindfulnessbased cancer recovery program on anxiety, depression, and mindfulness among patients with breast cancer.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
July 2024
Department of Nursing, Affiliated Hospital of Guangdong Medical University, Zhanjiang Guangdong 524001, China.
Objectives: The efficacy of monotherapy in alleviating psychological disorders like anxiety and depression among breast cancer patients is suboptimal, necessitating effective psychosocial interventions. Mindfulness-based interventions have been shown to mitigate anxiety-depression symptoms and encourage beneficial behaviors. The online mindfulness-based cancer recovery (MBCR) offers flexibility and guides practice across various settings, facilitating full patient engagement.
View Article and Find Full Text PDFAdvances in pharmacological treatment of Cushings disease.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
July 2024
Department of Endocrinology ＆Metabolism, West China Hospital, Sichuan University, Chengdu 610041.
Cushing's disease is a rare endocrine disorder characterized by hypercortisolism. Chronic elevated cortisol levels can lead to dysfunction or complications in multiple organs of systems, including cardiovascular, glucose, and bone metabolism, severely impacting patients' quality of life and posing life-threatening risks. Surgery is the first-line treatment for Cushing's disease.
View Article and Find Full Text PDFUnveiling immune resistance mechanisms in nasopharyngeal carcinoma and emerging targets for antitumor immune response: tertiary lymphoid structures.
J Transl Med
January 2025
Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Nasopharyngeal carcinoma (NPC) is a prevalent malignancy in China, commonly associated with undifferentiated cell types and Epstein-Barr virus (EBV) infection. The presence of intense lymphocytic infiltration and elevated expression of programmed cell death ligand 1(PD-L1) in NPC highlights its potential for immunotherapy, yet current treatment outcomes remain suboptimal. In this review, we explore the tumor microenvironment of NPC to better understand the mechanisms of resistance to immunotherapy, evaluate current therapeutic strategies, and pinpoint emerging targets, such as tertiary lymphoid structures (TLSs), that could enhance treatment outcomes and prognostic accuracy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!